Takeda Pharmaceutical Company Ltd

🇸🇪Sweden

Country: 🇸🇪Sweden

Ownership: -

Established: 1925-01-01

Employees: -

Market Cap: $47.5B

Website: http://www.takeda.co.jp/

Clinical Trials

A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Phase 3

Active, not recruiting

Conditions: Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)

Interventions: Drug: Ponatinib
Drug: Imatinib
Drug: Vincristine
Drug: Dexamethasone
Drug: Cytarabine
Drug: Methotrexate
Drug: Prednisone

First Posted Date: 2018-07-17

Last Posted Date: 2024-10-31

Lead Sponsor: Takeda

Target Recruit Count: 245

Registration Number: NCT03589326

Locations: 🇺🇸
Augusta University Georgia Cancer Center, Augusta, Georgia, United States
🇨🇦
Hopital Charles-LeMoyne, Greenfield Park, Quebec, Canada
🇧🇬
University Multiprofile Hospital for Active Treatment Saint Ivan Rilski, Sofia, Sofiya, Bulgaria

and more 89 locations

A Phase 2 Study of Cabozantinib in Japanese Participants With Advanced Hepatocellular Carcinoma

Phase 2

Completed

Conditions: Advanced Hepatocellular Carcinoma

Interventions: Drug: Cabozantinib

First Posted Date: 2018-07-16

Last Posted Date: 2023-04-18

Lead Sponsor: Takeda

Target Recruit Count: 34

Registration Number: NCT03586973

Locations: 🇯🇵
Hiroshima University Hospital, Hiroshima, Japan
🇯🇵
Okayama University Hospital, Okayama, Japan
🇯🇵
Yokohama City University Medical Center, Yokohama, Kanagawa, Japan

and more 14 locations

Specified Drug-Use Survey of Alogliptin and Metformin Hydrochloride Combination Tablets "Survey on Long-term Use in Type 2 Diabetes Mellitus Patients With Renal or Hepatic Impairment or Advanced Age"

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Alogliptin and Metformin hydrochloride

First Posted Date: 2018-06-13

Last Posted Date: 2023-09-13

Lead Sponsor: Takeda

Target Recruit Count: 1026

Registration Number: NCT03555565

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Specified Drug-Use Survey of Trelagliptin Tablets "Survey on Long-term Use in Patients With Type 2 Diabetes Mellitus"

Completed

Conditions: Type 2 Diabetes Mellitus

Interventions: Drug: Trelagliptin

First Posted Date: 2018-06-13

Last Posted Date: 2023-12-12

Lead Sponsor: Takeda

Target Recruit Count: 3198

Registration Number: NCT03555591

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

Specified Drug-Use Survey of Leuprorelin Acetate Injection Kit 11.25 mg "All-Case Investigation: Spinal and Bulbar Muscular Atrophy (SBMA)"

Recruiting

Conditions: Spinal and Bulbar Muscular Atrophy

Interventions: Drug: Leuprorelin Acetate

First Posted Date: 2018-06-13

Last Posted Date: 2024-02-02

Lead Sponsor: Takeda

Target Recruit Count: 300

Registration Number: NCT03555578

Locations: 🇯🇵
Takeda Selected Site, Tokyo, Japan

A Study to Determine Progression-free Survival (PFS) and Evaluate Participant Experience for Participants With Metastatic Anaplastic Lymphoma Kinase-positive (ALK+) Non-Small Cell Lung Cancer (NSCLC) Treated With Anaplastic Lymphoma Kinase (ALK) Inhibitors

Completed

Conditions: Anaplastic Lymphoma Kinase-positive
Carcinoma Non-small-cell Lung

Interventions: Drug: Brigatinib
Drug: Alectinib
Drug: Ceritinib
Drug: Lorlatinib
Drug: Any FDA Approved ALK Inhibitors

First Posted Date: 2018-06-06

Last Posted Date: 2024-07-15

Lead Sponsor: Takeda

Target Recruit Count: 111

Registration Number: NCT03546894

Locations: 🇺🇸
EmpiraMed, Inc., Maynard, Massachusetts, United States

A Study to Assess Clinical Effectiveness and Safety of Vedolizumab Intravenous in Real World Clinical Practice in Ulcerative Colitis (UC) Korean Participants

Completed

Conditions: Colitis, Ulcerative

First Posted Date: 2018-05-24

Last Posted Date: 2019-12-23

Lead Sponsor: Takeda

Target Recruit Count: 105

Registration Number: NCT03535649

Locations: 🇰🇷
Goo Hospital, Daegu, Korea, Republic of
🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
🇰🇷
Severance Hospital, Yonsei University Health System, Seoul, Korea, Republic of

and more 12 locations

A Study to Evaluate Disease Control and Treatment Pattern in Participants With Moderate to Severe Inflammatory Bowel Disease (IBD) in Real Life Practice

Completed

Conditions: Colitis, Ulcerative
Crohn Disease
Inflammatory Bowel Diseases

First Posted Date: 2018-05-22

Last Posted Date: 2024-03-29

Lead Sponsor: Takeda

Target Recruit Count: 1990

Registration Number: NCT03532932

Locations: 🇰🇿
Scientific-Research Institute of Cardiology and Internal Diseases, Gastroentorology department, Almaty, Almaty Region, Kazakhstan
🇷🇺
State Budgetary Healthcare Institution Irkutsk Order of the Badge of Honor Regional Clinical Hospital, Irkutsk, Irkutsk Region, Russian Federation
🇷🇺
Budgetary Institution "Surgut District Clinical Hospital", Surgut, Khanty-Mansi Autonomous Okrug-Yugra, Russian Federation

and more 31 locations

Immunogenicity and Safety of Tetravalent Dengue Vaccine (TDV) Co-administered With an Hepatitis A Virus Vaccine

Phase 3

Completed

Conditions: Healthy Volunteers

Interventions: Biological: TDV
Biological: HAV Vaccine
Biological: TDV Placebo
Biological: HAV Vaccine Placebo

First Posted Date: 2018-05-15

Last Posted Date: 2022-08-19

Lead Sponsor: Takeda

Target Recruit Count: 900

Registration Number: NCT03525119

Locations: 🇬🇧
Synexus - Midlands, Edgbaston, Birmingham, United Kingdom
🇬🇧
Synexus - Lancashire, Chorley, Lancashire, United Kingdom
🇬🇧
Synexus - Manchester, Manchester, United Kingdom

and more 7 locations

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of TAK-925 Study in Sleep-Deprived Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: TAK-925
Drug: TAK-925 Placebo
Drug: Modafinil
Drug: Modafinil Placebo

First Posted Date: 2018-05-11

Last Posted Date: 2021-03-26

Lead Sponsor: Takeda

Target Recruit Count: 20

Registration Number: NCT03522506

Locations: 🇺🇸
PRA Health Sciences, Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy